TW202221033A - Ｂ細胞惡性腫瘤的治療 - Google Patents

Ｂ細胞惡性腫瘤的治療 Download PDF

Info

Publication number
TW202221033A
TW202221033A TW110128346A TW110128346A TW202221033A TW 202221033 A TW202221033 A TW 202221033A TW 110128346 A TW110128346 A TW 110128346A TW 110128346 A TW110128346 A TW 110128346A TW 202221033 A TW202221033 A TW 202221033A
Authority
TW
Taiwan
Prior art keywords
binding fragment
baffr antibody
combination
baffr
cell
Prior art date
Application number
TW110128346A
Other languages
English (en)
Chinese (zh)
Inventor
納迪亞 哈蘇納
安威莎 喬胡里
蘇莫許 喬胡里
長熙 胡
妮可 安居 旁遮普 昆達莫
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202221033A publication Critical patent/TW202221033A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Seeds, Soups, And Other Foods (AREA)
TW110128346A 2020-08-04 2021-08-02 Ｂ細胞惡性腫瘤的治療 TW202221033A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063060786P 2020-08-04 2020-08-04
US63/060,786 2020-08-04
US202063114363P 2020-11-16 2020-11-16
US63/114,363 2020-11-16
US202163147507P 2021-02-09 2021-02-09
US63/147,507 2021-02-09

Publications (1)

Publication Number Publication Date
TW202221033A true TW202221033A (zh) 2022-06-01

Family

ID=77448106

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110128346A TW202221033A (zh) 2020-08-04 2021-08-02 Ｂ細胞惡性腫瘤的治療

Country Status (10)

Country Link
US (1) US20230279132A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192869A1 (cg-RX-API-DMAC10.html)
JP (1) JP7834711B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230042594A (cg-RX-API-DMAC10.html)
CN (1) CN116133687A (cg-RX-API-DMAC10.html)
AU (1) AU2021320129B2 (cg-RX-API-DMAC10.html)
CA (1) CA3190678A1 (cg-RX-API-DMAC10.html)
IL (1) IL300086A (cg-RX-API-DMAC10.html)
TW (1) TW202221033A (cg-RX-API-DMAC10.html)
WO (1) WO2022031567A1 (cg-RX-API-DMAC10.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2009272771B2 (en) 2008-07-17 2012-09-20 Novartis Ag Compositions and methods of use for therapeutic antibodies
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
CA3160207A1 (en) * 2019-11-06 2021-05-14 Novartis Ag Treatment for sjogren's syndrome

Also Published As

Publication number Publication date
JP2023536596A (ja) 2023-08-28
AU2021320129B2 (en) 2025-12-18
KR20230042594A (ko) 2023-03-28
JP7834711B2 (ja) 2026-03-24
WO2022031567A1 (en) 2022-02-10
US20230279132A1 (en) 2023-09-07
AU2021320129A1 (en) 2023-03-16
CA3190678A1 (en) 2022-02-10
CN116133687A (zh) 2023-05-16
EP4192869A1 (en) 2023-06-14
IL300086A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
KR102776925B1 (ko) Flt3l-fc 융합 단백질 및 사용 방법
TWI823906B (zh) 抗-cd73 抗體及其使用方法
TW202140567A (zh) 嵌合抗原及t細胞受體以及使用方法
KR20200142542A (ko) Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
TW202332699A (zh) 靶向５ｔ４之抗體及其用途
JP2023551535A (ja) Ｔ細胞がんを治療するための方法および材料
TW202128755A (zh) 抗原結合蛋白
AU2021320129B2 (en) Treatment of B cell malignancies
AU2021320130B2 (en) Treatment of CLL
EA045919B1 (ru) СЛИТЫЕ БЕЛКИ FLT3L-Fc И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2026040955A1 (zh) 双特异性抗cd3/cd20多肽复合物的用途
WO2026090160A2 (en) Cd4-targeted il-15 molecules and methods of use
HK40071848A (en) Flt3l-fc fusion proteins and methods of use
HK40071848B (en) Flt3l-fc fusion proteins and methods of use
HK40128442A (en) Chimeric antigen and t cell receptors and methods of use